AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02398162 — intervention group
Intervention type: PROCEDURE
Intervention: Multi Blood Collections
Description: At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
Study NCT02398162 — intervention group
Intervention type: PROCEDURE
Intervention: Single Blood Collection
Description: On the enrollment day
Study NCT03317379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
Study NCT03317379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support mentorship
Description: Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
Study NCT03317379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record use with mentor
Description: Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
Study NCT01287793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: intravenous, 200 mg, single dose
Study NCT01287793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: intravenous, 50 mg, single dose
Study NCT01287793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: oral tablet, 400 mg, single dose
Study NCT01287793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mL 0.9% Sodium Chloride intravenous
Description: intravenous fluid, 100 mL, single dose
Study NCT01287793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% Sodium Chloride intravenous 100mL, single dose
Study NCT03079505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 MG [Sprycel]
Description: Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
Study NCT03079505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 150mg oral capsule [Tasigna]
Description: Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
Study NCT00488241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zarzenda
Description: Topically applied daily for 2 weeks
Study NCT03499574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dysphagia therapy using surface EMG as biofeedback
Description: 10 x 45 minute sessions over 14 days
Study NCT03499574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
Study NCT03499574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
Study NCT04788030 — intervention group
Intervention type: OTHER
Intervention: Nerve reconstruction
Description: Nerve bridging with muscle-in-vein conduits
Study NCT01244139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
Study NCT01244139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion dummy drug
Study NCT00759824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin, cyclophosphamide, vindesine, valproic acid
Description: Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
Study NCT04703803 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1% lidocaine injection in trigger points
Description: The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
Study NCT03497715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Wockhardt)
Description: Reference 2
Study NCT05592977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Oral Distalizing Device
Description: The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
Study NCT01079247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive transfusion threshold
Description: maintain hemoglobin at 7-8 g/dL
Study NCT01079247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion threshold
Description: Maintain hemoglobin at 10-11 g/dL
Study NCT02660515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional wrist arthroscopy
Study NCT02660515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF
Study NCT01727661 — intervention group
Intervention type: BEHAVIORAL
Intervention: exercise testing with near-infrared spectroscopy
Description: subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
Study NCT01727661 — intervention group
Intervention type: BEHAVIORAL
Intervention: lung function testing
Description: spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds.
Study NCT01727661 — intervention group
Intervention type: BEHAVIORAL
Intervention: quality of life
Description: assessing quality of life using short-forum 36 (questionnaire)
Study NCT03516097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured school based intervention
Description: Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
Study NCT03516097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured school based intervention
Description: Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
Study NCT03516097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile app usage
Description: The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
Study NCT02661633 — intervention group
Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
Study NCT02661633 — intervention group
Intervention type: DEVICE
Intervention: Advanced MRI Neuroimaging
Description: Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
Study NCT03713320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Description: At least weekly doses of cobomarsen (282 mg) throughout study treatment period
Study NCT03713320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: Daily doses of vorinostat throughout study treatment period
Study NCT00823836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropinirole PR/XR
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
Study NCT00823836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole PR/XR
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
Study NCT00823836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropinirole IR
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
Study NCT04454099 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4 kind of FOBT and colonoscopy with pathological examination
Description: Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
Study NCT00776022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
Study NCT00776022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
Study NCT01945398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
Study NCT01945398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SHAM
Description: Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
Study NCT03874936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24mg Solution for Injection
Description: Administrated i.v.
Study NCT03874936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution for Injection
Description: administrated i.v.
Study NCT03874936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: administrated i.v.
Study NCT02868671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT02868671 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Study NCT04135508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1406
Description: 40mg/0.8ml
Study NCT04135508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: 40mg/0.8ml
Study NCT00924222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sedation with sevoflurane
Study NCT00924222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation on intensive care unit with propofol
Study NCT02900235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995
Study NCT03537235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libramed
Study NCT03537235 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04226092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPSkin Barrier Pro
Description: This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
Study NCT04226092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquaflux AF200
Description: This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
Study NCT01993277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexalin Brain Stimulator
Study NCT01993277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fischer Wallace Stimulator
Study NCT01993277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: David Delight Stimulator
Study NCT01993277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Study NCT00813982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A Experimental Contact Lens
Description: Experimental spherical, silicone hydrogel soft contact lens
Study NCT00813982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A Commercial Contact Lens
Description: Commercially marketed spherical, silicone hydrogel soft contact lens
Study NCT03338647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEB
Description: Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
Study NCT03338647 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: High precision radiation therapy to the liver tumor(s)
Study NCT01781832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI-Derived Shear Wave Velocities
Description: An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
Study NCT04171349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: Vial
Study NCT04171349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Vial
Study NCT04171349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Vial
Study NCT02719743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
Study NCT02719743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
Study NCT02990468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: Subcutaneous injection.
Study NCT02990468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive standard dose intensity modulated radiation therapy (IMRT).
Study NCT02990468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered per institution's standard of care practice.
Study NCT00085566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT00085566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study NCT04092452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg QD
Study NCT04092452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 45 mg QD
Study NCT04092452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647
Description: 400 mg QD
Study NCT04092452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03672942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
Study NCT03672942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
Study NCT03672942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
Study NCT04430166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: 200mg / intravenous drip, once every three weeks
Study NCT03439618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: time-restricted feeding
Description: At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.
Study NCT03439618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: continuous feeding
Description: At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
Study NCT01912989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.